Twice daily tripotassium dicitrato bismuthate in the treatment of duodenal ulceration.
Fifty three patients with endoscopically proven duodenal ulceration have cooperated in a clinical trial to compare the ulcer healing effect of tripotassium dicitrato bismuthate (TDB) at standard dosage administered either twice or four times daily. No statistically significant difference has been found to exist between ulcer healing in the two groups at 4 weeks (72% and 67%, P = 0.944) or at 8 weeks (92% and 81%, P = 0.504) and it is concluded that twice daily TDB maintains the effectiveness of the drug and has advantages for patient compliance.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001729:Bismuth / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004381:Duodenal Ulcer / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds
D009942:Organometallic Compounds; C002791:bismuth tripotassium dicitrate; D001729:Bismuth